Laurus Labs shares rally over 4% as Q1FY27 profit jumps 126% on strong CDMO growth

Laurus Labs reported consolidated net profit of Rs 368 crore for Q1FY27, up 126% year-on-year from Rs 163 crore, driven by strong growth in its CDMO segment and steady momentum in affordable medicines. Revenue from operations grew 29% YoY to Rs 2,026 crore, while EBITDA expanded to Rs 644 crore with margin improving 700 basis points to 31.8%. FII stake in the company rose from 25.82% to 28% during the June 2026 quarter, reflecting stronger institutional interest, and the stock has gained nearly 92% over the past year.